Breast Cancer:@0.781548:0.035749:0.914554:0.035749:0.914554:0.019993:0.781548:0.019993:0.011045:0.005717:0.012508:0.013143:0.007466:0.006523:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
53:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
neoadjuvant versus adjuvant chemother-:@0.121195:0.094740:0.475751:0.094740:0.475751:0.080735:0.121195:0.080735:0.010434:0.011118:0.011203:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.008347:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.008347:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.008347:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005131:0.005679
apy in early breast cancer:  meta-analysis :@0.121195:0.108886:0.480491:0.108886:0.480491:0.094881:0.121195:0.094881:0.011682:0.011665:0.009168:0.007406:0.003421:0.010434:0.007406:0.011118:0.011682:0.005148:0.003421:0.009168:0.007406:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.007406:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.002653:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738
of  individual  patient  data from  ten  ran-:@0.121195:0.123033:0.475765:0.123033:0.475765:0.109027:0.121195:0.109027:0.011203:0.005371:0.004738:0.005273:0.003421:0.010434:0.011716:0.003421:0.009476:0.003421:0.011716:0.010399:0.011682:0.003421:0.004738:0.005296:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.004738:0.005277:0.011716:0.011682:0.005798:0.011682:0.010023:0.005371:0.005078:0.011203:0.016044:0.004738:0.005273:0.005798:0.011118:0.010434:0.004738:0.005272:0.005148:0.011682:0.010434:0.005679
domised trials. :@0.121195:0.137179:0.242636:0.137179:0.242636:0.123174:0.121195:0.123174:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.004002:0.005798:0.005148:0.003421:0.011682:0.003421:0.006636:0.004738:0.004738
Lancet Oncol:@0.241901:0.137179:0.354880:0.137179:0.354880:0.123174:0.241901:0.123174:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.003990:0.014864:0.010434:0.011067:0.011203:0.003421
. 2018;19(1):27. :@0.354880:0.137179:0.480491:0.137179:0.480491:0.123174:0.354880:0.123174:0.004738:0.004002:0.009476:0.009476:0.009476:0.009489:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.004738:0.004738
Epub 2017 Dec 11.:@0.121195:0.151325:0.274809:0.151325:0.274809:0.137320:0.121195:0.137320:0.009168:0.011665:0.010399:0.011665:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012726:0.011118:0.011067:0.004738:0.009476:0.009476:0.004738
6. :@0.084848:0.165472:0.103800:0.165472:0.103800:0.151466:0.084848:0.151466:0.009476:0.004738:0.004738
 Cortazar  P, Zhang L, :@0.121195:0.165472:0.317350:0.165472:0.317350:0.151466:0.121195:0.151466:0.000000:0.013906:0.011203:0.005148:0.005798:0.011682:0.007269:0.011682:0.005148:0.004738:0.009224:0.008019:0.004738:0.013974:0.008210:0.010434:0.011682:0.010434:0.011511:0.013974:0.007902:0.004738:0.004738
et al:@0.326586:0.165472:0.372580:0.165472:0.372580:0.151466:0.326586:0.151466:0.011118:0.005798:0.013974:0.011682:0.003421
. Pathologi-:@0.372580:0.165472:0.475751:0.165472:0.475751:0.151466:0.372580:0.151466:0.004738:0.013974:0.010126:0.011682:0.005798:0.010434:0.011203:0.003421:0.011203:0.011511:0.003402:0.005679
cal complete response and long-term :@0.121195:0.179618:0.480508:0.179618:0.480508:0.165613:0.121195:0.165613:0.011067:0.011682:0.003421:0.014607:0.011067:0.011203:0.016044:0.011665:0.003421:0.011118:0.005798:0.011118:0.014607:0.005078:0.011118:0.006636:0.011665:0.011203:0.010434:0.006636:0.011118:0.014607:0.011682:0.010434:0.011716:0.014607:0.003421:0.011203:0.010434:0.011511:0.005679:0.005798:0.011118:0.005614:0.016044:0.004738
clinical  benefit  in  breast  cancer:  the  CT-:@0.121195:0.193765:0.475760:0.193765:0.475760:0.179759:0.121195:0.179759:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.004086:0.011665:0.011118:0.010434:0.011118:0.004165:0.004165:0.005798:0.004738:0.004066:0.003421:0.010434:0.004738:0.004074:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.004738:0.004076:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.004064:0.005798:0.010434:0.011118:0.004738:0.004067:0.013906:0.007286:0.005679
NeoBC pooled analysis. :@0.121195:0.207911:0.346306:0.207911:0.346306:0.193906:0.121195:0.193906:0.012657:0.011118:0.011203:0.009818:0.013906:0.016762:0.011665:0.011203:0.011203:0.003421:0.011118:0.011716:0.016762:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.004738
Lancet:@0.358347:0.207911:0.416348:0.207911:0.416348:0.193906:0.358347:0.193906:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798
. 2014 :@0.416348:0.207911:0.480489:0.207911:0.480489:0.193906:0.416348:0.193906:0.004738:0.016762:0.009476:0.009476:0.009476:0.009476:0.004738
Jul;384(9938):164-72.:@0.121195:0.222057:0.289485:0.222057:0.289485:0.208052:0.121195:0.208052:0.008244:0.010399:0.003421:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
7. :@0.084848:0.236204:0.103800:0.236204:0.103800:0.222198:0.084848:0.222198:0.009476:0.004738:0.004738
 Gianni L, Pienkowski T, :@0.121195:0.236204:0.313684:0.236204:0.313684:0.222198:0.121195:0.222198:0.000000:0.014915:0.003421:0.011682:0.010434:0.010434:0.003421:0.007594:0.007902:0.004738:0.007594:0.010126:0.003421:0.011118:0.010434:0.008586:0.011203:0.014214:0.006636:0.008586:0.003421:0.007594:0.005538:0.004738:0.004738
et al:@0.316541:0.236204:0.356154:0.236204:0.356154:0.222198:0.316541:0.222198:0.011118:0.005798:0.007594:0.011682:0.003421
.  Efficacy  and :@0.356154:0.236204:0.480501:0.236204:0.480501:0.222198:0.356154:0.222198:0.004738:0.004738:0.002853:0.009168:0.005371:0.004165:0.004165:0.011067:0.011682:0.011067:0.009168:0.004738:0.002858:0.011682:0.010434:0.011716:0.004738
safety of neoadjuvant pertuzumab and :@0.121195:0.250350:0.480477:0.250350:0.480477:0.236345:0.121195:0.236345:0.006636:0.011682:0.005371:0.011118:0.005798:0.009168:0.011443:0.011203:0.005371:0.011443:0.010434:0.011118:0.011203:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.011443:0.011665:0.011118:0.005148:0.005798:0.010399:0.007269:0.010399:0.016032:0.011682:0.011665:0.011443:0.011682:0.010434:0.011716:0.004738
trastuzumab in women with locally  ad-:@0.121195:0.264496:0.475763:0.264496:0.475763:0.250491:0.121195:0.250491:0.005798:0.005148:0.011682:0.006636:0.005798:0.010399:0.007269:0.010399:0.016044:0.011682:0.011665:0.011768:0.003421:0.010434:0.011768:0.014214:0.011203:0.016044:0.011118:0.010434:0.011768:0.014214:0.003421:0.005798:0.010434:0.011768:0.003421:0.011203:0.011067:0.011682:0.003421:0.003421:0.009168:0.004738:0.007042:0.011682:0.011716:0.005679
vanced,  inflammatory,  or  early  HER2-pos-:@0.121195:0.278643:0.475748:0.278643:0.475748:0.264638:0.121195:0.264638:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.004738:0.004738:0.003317:0.003421:0.010434:0.004148:0.004148:0.011682:0.016044:0.016044:0.011682:0.005798:0.011203:0.005148:0.009168:0.004738:0.004738:0.003308:0.011203:0.005148:0.004738:0.003310:0.011118:0.011682:0.005148:0.003421:0.009168:0.004738:0.003318:0.011682:0.009168:0.010382:0.009476:0.005679:0.011665:0.011203:0.006636:0.005679
itive breast cancer  (NeoSphere): a ran-:@0.121195:0.292789:0.475767:0.292789:0.475767:0.278784:0.121195:0.278784:0.003421:0.005798:0.003421:0.009476:0.011118:0.010793:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.010793:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.006046:0.006312:0.012657:0.011118:0.011203:0.008518:0.011665:0.010434:0.011118:0.005070:0.011118:0.006312:0.004738:0.010793:0.011682:0.010793:0.005148:0.011682:0.010434:0.005679
domised multicentre, open-label, phase 2 :@0.121195:0.306936:0.480486:0.306936:0.480486:0.292930:0.121195:0.292930:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.006782:0.016044:0.010399:0.003421:0.005798:0.003421:0.011067:0.011118:0.010434:0.005798:0.005073:0.011118:0.004738:0.006775:0.011203:0.011665:0.011118:0.010434:0.005679:0.003421:0.011682:0.011665:0.011118:0.003421:0.004738:0.006775:0.011665:0.010434:0.011682:0.006636:0.011118:0.006782:0.009476:0.004738
trial. :@0.121195:0.321082:0.160142:0.321082:0.160142:0.307077:0.121195:0.307077:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Lancet Oncol.:@0.160142:0.321082:0.278607:0.321082:0.278607:0.307077:0.160142:0.307077:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2012;13(1):25.:@0.278589:0.321082:0.395446:0.321082:0.395446:0.307077:0.278589:0.307077:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.004738
8. :@0.084848:0.335228:0.103800:0.335228:0.103800:0.321223:0.084848:0.321223:0.009476:0.004738:0.004738
 Geffen S, Abu-Ghanem N, :@0.121195:0.335228:0.355662:0.335228:0.355662:0.321223:0.121195:0.321223:0.000000:0.014915:0.011118:0.005420:0.005371:0.011118:0.010434:0.008588:0.008518:0.004738:0.008501:0.012657:0.011665:0.010399:0.005679:0.014915:0.010434:0.011682:0.010434:0.011118:0.016044:0.008586:0.012657:0.004738:0.004738
 :@0.179571:0.335228:0.184360:0.335228:0.184360:0.320976:0.179571:0.320976:0.004789
 :@0.324942:0.335228:0.329731:0.335228:0.329731:0.320976:0.324942:0.320976:0.004789
et al:@0.359425:0.335228:0.399945:0.335228:0.399945:0.321223:0.359425:0.321223:0.011118:0.005798:0.008501:0.011682:0.003421
. The im-:@0.399945:0.335228:0.475768:0.335228:0.475768:0.321223:0.399945:0.321223:0.004738:0.008603:0.007286:0.010434:0.011118:0.008501:0.003421:0.016044:0.005679
 :@0.404683:0.335228:0.409472:0.335228:0.409472:0.320976:0.404683:0.320976:0.004789
pact of the 21-gene recurrence score :@0.121212:0.349375:0.480527:0.349375:0.480527:0.335369:0.121212:0.335369:0.011665:0.011682:0.011067:0.005798:0.012982:0.011203:0.005371:0.012982:0.005798:0.010434:0.011118:0.012982:0.009476:0.009476:0.005679:0.011511:0.011118:0.010434:0.011118:0.012982:0.005078:0.011118:0.011067:0.010399:0.005148:0.005070:0.011118:0.010434:0.011067:0.011118:0.012982:0.006636:0.011067:0.011203:0.005078:0.011118:0.004738
assay on decision making about adjuvant :@0.560606:0.094740:0.919916:0.094740:0.919916:0.080735:0.560606:0.080735:0.011682:0.006636:0.006636:0.011682:0.009168:0.006209:0.011203:0.010434:0.006209:0.011716:0.011118:0.011067:0.003421:0.006636:0.003421:0.011203:0.010434:0.006199:0.016044:0.011682:0.008586:0.003421:0.010434:0.011511:0.006200:0.011682:0.011665:0.011203:0.010399:0.005798:0.006209:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004738
chemotherapy  in early-stage estrogen-:@0.560606:0.108886:0.915191:0.108886:0.915191:0.094881:0.560606:0.094881:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.010020:0.003421:0.010434:0.014778:0.011118:0.011682:0.005148:0.003421:0.009168:0.005679:0.006636:0.005798:0.011682:0.011511:0.011118:0.014778:0.011118:0.006636:0.005798:0.005078:0.011203:0.011511:0.011118:0.010434:0.005679
receptor-positive  breast  cancer  in  an  on-:@0.560606:0.123033:0.915174:0.123033:0.915174:0.109027:0.560606:0.109027:0.005078:0.011118:0.011067:0.011118:0.011665:0.005798:0.011203:0.005148:0.005679:0.011665:0.011203:0.006636:0.003421:0.005798:0.003421:0.009476:0.011118:0.004738:0.002894:0.011665:0.005082:0.011118:0.011682:0.006636:0.005798:0.004738:0.002899:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.002891:0.003421:0.010434:0.004738:0.002899:0.011682:0.010434:0.004738:0.002899:0.011203:0.010434:0.005679
cology  practice  with  a  unified  treatment :@0.560606:0.137179:0.919916:0.137179:0.919916:0.123174:0.560606:0.123174:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.003698:0.011665:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004738:0.003703:0.014214:0.003421:0.005798:0.010434:0.004738:0.003703:0.011682:0.004738:0.003705:0.010399:0.010434:0.003421:0.004165:0.004165:0.011118:0.011716:0.004738:0.003700:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
policy. :@0.560606:0.151325:0.620027:0.151325:0.620027:0.137320:0.560606:0.137320:0.011665:0.011203:0.003421:0.003421:0.011067:0.009168:0.004738:0.004738
Annals of Oncology:@0.624388:0.151325:0.797296:0.151325:0.797296:0.137320:0.624388:0.137320:0.012657:0.010434:0.010434:0.011682:0.003421:0.006636:0.009100:0.011203:0.005371:0.009100:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
. 2011 Nov;22 :@0.797296:0.151325:0.919911:0.151325:0.919911:0.137320:0.797296:0.137320:0.004738:0.009100:0.009476:0.009476:0.009486:0.009476:0.009100:0.012657:0.011203:0.009476:0.004738:0.009476:0.009476:0.004738
(11):2381-2386.:@0.560606:0.165472:0.683142:0.165472:0.683142:0.151466:0.560606:0.151466:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
9. :@0.524259:0.179618:0.543211:0.179618:0.543211:0.165613:0.524259:0.165613:0.009476:0.004738:0.004738
  Pagani O, Regan MM, :@0.560606:0.179618:0.756740:0.179618:0.756740:0.165613:0.560606:0.165613:0.004738:-0.004738:0.010126:0.011682:0.011511:0.011682:0.010434:0.003421:0.007209:0.014864:0.004738:0.007218:0.010382:0.011118:0.011511:0.011682:0.010434:0.007208:0.015719:0.015719:0.004738:0.004738
et al:@0.759205:0.179618:0.798432:0.179618:0.798432:0.165613:0.759205:0.165613:0.011118:0.005798:0.007208:0.011682:0.003421
. International :@0.798432:0.179618:0.919905:0.179618:0.919905:0.165613:0.798432:0.165613:0.004738:0.007208:0.003866:0.010434:0.005798:0.011118:0.005499:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738
Breast Cancer Study Group. Adjuvant :@0.560606:0.193765:0.919919:0.193765:0.919919:0.179759:0.560606:0.179759:0.009818:0.005082:0.011118:0.011682:0.006636:0.005798:0.015462:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.015462:0.008518:0.005798:0.010399:0.011716:0.009168:0.015462:0.014915:0.005080:0.011203:0.010399:0.011665:0.004738:0.015462:0.012657:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004738
exemestane with ovarian suppression :@0.560606:0.207911:0.919902:0.207911:0.919902:0.193906:0.560606:0.193906:0.011118:0.008210:0.011118:0.016044:0.011118:0.006636:0.005798:0.011682:0.010434:0.011118:0.019824:0.014214:0.003421:0.005798:0.010434:0.019824:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.019824:0.006636:0.010399:0.011665:0.011665:0.005082:0.011118:0.006636:0.006636:0.003421:0.011203:0.010434:0.004738
in premenopausal  breast cancer. TEXT :@0.560606:0.222057:0.919914:0.222057:0.919914:0.208052:0.560606:0.208052:0.003421:0.010434:0.014607:0.011665:0.005077:0.011118:0.016044:0.011118:0.010434:0.011203:0.011665:0.011682:0.010399:0.006636:0.011682:0.003421:0.004738:0.009879:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.014607:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.014607:0.007286:0.009168:0.010417:0.007286:0.004738
and SOFT  Investigators:@0.560606:0.236204:0.761329:0.236204:0.761329:0.222198:0.560606:0.222198:0.011682:0.010434:0.011716:0.012606:0.008518:0.014864:0.008296:0.007286:0.004738:0.007854:0.003866:0.010434:0.009476:0.011118:0.006636:0.005798:0.003421:0.011511:0.011682:0.005798:0.011203:0.005148:0.006636
.  N  Engl J  Med:@0.761329:0.236204:0.910447:0.236204:0.910447:0.222198:0.761329:0.222198:0.004738:0.004738:0.007858:0.012657:0.004738:0.007856:0.009168:0.010434:0.011511:0.003421:0.012606:0.008244:0.004738:0.007858:0.015719:0.011118:0.011716
. :@0.910447:0.236204:0.919923:0.236204:0.919923:0.222198:0.910447:0.222198:0.004738:0.004738
2014;371(2):107.:@0.560606:0.250350:0.691677:0.250350:0.691677:0.236345:0.560606:0.236345:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.004738
10.   Pan H, Gray R, :@0.524259:0.264496:0.685793:0.264496:0.685793:0.250491:0.524259:0.250491:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.011682:0.010434:0.005251:0.011682:0.004738:0.005251:0.014915:0.005148:0.011682:0.009168:0.005251:0.010382:0.004738:0.004738
et al:@0.686306:0.264496:0.723576:0.264496:0.723576:0.250491:0.686306:0.250491:0.011118:0.005798:0.005251:0.011682:0.003421
. 20-Year risks of breast-:@0.723576:0.264496:0.915168:0.264496:0.915168:0.250491:0.723576:0.250491:0.004738:0.005251:0.009476:0.009476:0.005679:0.008609:0.011118:0.011682:0.005148:0.005251:0.005148:0.003421:0.006636:0.008586:0.006636:0.005251:0.011203:0.005371:0.005251:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.005679
cancer recurrence after stopping endo-:@0.560606:0.278643:0.915185:0.278643:0.915185:0.264638:0.560606:0.264638:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.010211:0.005078:0.011118:0.011067:0.010399:0.005148:0.005070:0.011118:0.010434:0.011067:0.011118:0.010211:0.011682:0.005371:0.005798:0.011118:0.005148:0.010211:0.006636:0.005798:0.011203:0.011665:0.011665:0.003421:0.010434:0.011511:0.010211:0.011118:0.010434:0.011716:0.011203:0.005679
crine therapy at 5 years. EBCTCG :@0.560606:0.292789:0.846297:0.292789:0.846297:0.278784:0.560606:0.278784:0.011067:0.005148:0.003421:0.010434:0.011118:0.006057:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006063:0.011682:0.005798:0.006060:0.009476:0.006063:0.009168:0.011118:0.011682:0.005148:0.006636:0.004738:0.006062:0.009168:0.009818:0.013906:0.007286:0.013906:0.014915:0.004738
N Engl J :@0.847617:0.292789:0.919909:0.292789:0.919909:0.278784:0.847617:0.278784:0.012657:0.006057:0.009168:0.010434:0.011511:0.003421:0.006062:0.008244:0.004738
Med:@0.560606:0.306936:0.599159:0.306936:0.599159:0.292930:0.560606:0.292930:0.015719:0.011118:0.011716
. 2017;377(19):1836.:@0.599159:0.306936:0.758657:0.306936:0.758657:0.292930:0.599159:0.292930:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
11.   Davies  C, Pan H, :@0.524259:0.321082:0.713943:0.321082:0.713943:0.307077:0.524259:0.307077:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.012726:0.011682:0.009476:0.003421:0.011118:0.006636:0.004738:0.004016:0.013906:0.004738:0.008740:0.010126:0.011682:0.010434:0.008740:0.011682:0.004738:0.004738
et al:@0.717946:0.321082:0.758705:0.321082:0.758705:0.307077:0.717946:0.307077:0.011118:0.005798:0.008740:0.011682:0.003421
. Adjuvant tamox-:@0.758705:0.321082:0.915176:0.321082:0.915176:0.307077:0.758705:0.307077:0.004738:0.008740:0.012657:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.008740:0.005798:0.011682:0.016044:0.011203:0.008210:0.005679
ifen: longer against shorter (ATLAS). :@0.560606:0.335228:0.852731:0.335228:0.852731:0.321223:0.560606:0.321223:0.003421:0.005371:0.011118:0.010434:0.004738:0.004464:0.003421:0.011203:0.010434:0.011511:0.011118:0.005148:0.004451:0.011682:0.011511:0.011682:0.003421:0.010434:0.006636:0.005798:0.004464:0.006636:0.010434:0.011203:0.005148:0.005798:0.011118:0.005148:0.004447:0.006312:0.011268:0.007286:0.007902:0.012657:0.008518:0.006312:0.004738:0.004738
Lancet.:@0.852441:0.335228:0.915179:0.335228:0.915179:0.321223:0.852441:0.321223:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738
 :@0.915162:0.335228:0.919900:0.335228:0.919900:0.321223:0.915162:0.321223:0.004738
2013;381(9869):805:@0.560606:0.349375:0.715366:0.349375:0.715366:0.335369:0.560606:0.335369:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476
. :@0.715418:0.349375:0.724893:0.349375:0.724893:0.335369:0.715418:0.335369:0.004738:0.004738